Clinical Trial Update: Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for Durvalumab as second-line therapy in recurrent stage IV squamous cell lung cancer without matching biomarkers; trial phases 2 and 3 co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Squamous Cell Lung Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-12-30